Back to results
US 11,332,427 B2Granted
Menaquinol compositions and methods of treatment
AssigneeEpizon Pharma, Inc.
InventorsKeith E. Drouet, James A. Tumlin, John M. Rudey
Life of this patent
Estimating the term…
Abstract
The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.
Claims21
A method of treating, preventing, slowing the progression of, arresting, and/or reversing calciphylaxis in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising substantially pure menaquinol compound of the Formula I:
- and a pharmaceutically acceptable excipient, to prevent, slow the progression of, arrest, or reverse calciphylaxis, wherein:
- m is 7, 8, 9 or 10;
- R1 and R2 are both the residue 15;
- R1 and R2 are both the residue 16;
- R1 and R2 are both the residue 17;
- R1 and R2 are both the residue 18;
- R1 and R2 are both the residue 20;
- R1 and R2 are both the residue 21;
- R1 and R2 are both the residue 22;
- R1 and R2 are both the residue 23;
- R1 and R2 are both the residue 24;
- R1 and R2 are both the residue 25;
- R1 and R2 are both the residue 26;
- R1 and R2 are both the residue 27;
- R1 and R2 are both the residue 28;
- R1 is H and R2 is the residue 15;
- R2 is H and R1 is the residue 15;
- R1 is H and R2 is the residue 16;
- R2 is H and R1 is the residue 16;
- R1 is H and R2 is the residue 17;
- R2 is H and R1 is the residue 17;
- R1 is H and R2 is the residue 18;
- R2 is H and R1 is the residue 18;
- R1 is H and R2 is the residue 20;
- R2 is H and R1 is the residue 20;
- R1 is H and R2 is the residue 21;
- R2 is H and R1 is the residue 21;
- R1 is H and R2 is the residue 22;
- R2 is H and R1 is the residue 22;
- R1 is H and R2 is the residue 23;
- R2 is H and R1 is the residue 23;
- R1 is H and R2 is the residue 24;
- R2 is H and R1 is the residue 24;
- R1 is H and R2 is the residue 25;
- R2 is H and R1 is the residue 25;
- R1 is H and R2 is the residue 26;
- R2 is H and R1 is the residue 26;
- R1 is H and R2 is the residue 27;
- R2 is H and R1 is the residue 27;
- and
- R1 is H and R2 is the residue 28;
- R2 is H and R1 is the residue 28;
39 more elements
A method of treating calciphylaxis in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising substantially pure menaquinol compound of the Formula I:
- and a pharmaceutically acceptable excipient, to treat calciphylaxis, wherein:
- m is 7, 8, 9 or 10;
- R1 and R2 are both the residue 15;
- R1 and R2 are both the residue 16;
- R1 and R2 are both the residue 17;
- R1 and R2 are both the residue 18;
- R1 and R2 are both the residue 20;
- R1 and R2 are both the residue 21;
- R1 and R2 are both the residue 22;
- R1 and R2 are both the residue 23;
- R1 and R2 are both the residue 24;
- R1 and R2 are both the residue 25;
- R1 and R2 are both the residue 26;
- R1 and R2 are both the residue 27;
- R1 and R2 are both the residue 28;
- R1 is H and R2 is the residue 15;
- R2 is H and R1 is the residue 15;
- R1 is H and R2 is the residue 16;
- R2 is H and R1 is the residue 16;
- R1 is H and R2 is the residue 17;
- R2 is H and R1 is the residue 17;
- R1 is H and R2 is the residue 18;
- R2 is H and R1 is the residue 18;
- R1 is H and R2 is the residue 20;
- R2 is H and R1 is the residue 20;
- R1 is H and R2 is the residue 21;
- R2 is H and R1 is the residue 21;
- R1 is H and R2 is the residue 22;
- R2 is H and R1 is the residue 22;
- R1 is H and R2 is the residue 23;
- R2 is H and R1 is the residue 23;
- R1 is H and R2 is the residue 24;
- R2 is H and R1 is the residue 24;
- R1 is H and R2 is the residue 25;
- R2 is H and R1 is the residue 25;
- R1 is H and R2 is the residue 26;
- R2 is H and R1 is the residue 26;
- R1 is H and R2 is the residue 27;
- R2 is H and R1 is the residue 27;
- and
- R1 is H and R2 is the residue 28;
- R2 is H and R1 is the residue 28;
39 more elements
A method of reversing calciphylaxis in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a composition comprising substantially pure menaquinol compound of the Formula I:
- and a pharmaceutically acceptable excipient, to reverse calciphylaxis, wherein:
- m is 7, 8, 9 or 10;
- R1 and R2 are both the residue 15;
- R1 and R2 are both the residue 16;
- R1 and R2 are both the residue 17;
- R1 and R2 are both the residue 18;
- R1 and R2 are both the residue 20;
- R1 and R2 are both the residue 21;
- R1 and R2 are both the residue 22;
- R1 and R2 are both the residue 23;
- R1 and R2 are both the residue 24;
- R1 and R2 are both the residue 25;
- R1 and R2 are both the residue 26;
- R1 and R2 are both the residue 27;
- R1 and R2 are both the residue 28;
- R1 is H and R2 is the residue 15;
- R2 is H and R1 is the residue 15;
- R1 is H and R2 is the residue 16;
- R2 is H and R1 is the residue 16;
- R1 is H and R2 is the residue 17;
- R2 is H and R1 is the residue 17;
- R1 is H and R2 is the residue 18;
- R2 is H and R1 is the residue 18;
- R1 is H and R2 is the residue 20;
- R2 is H and R1 is the residue 20;
- R1 is H and R2 is the residue 21;
- R2 is H and R1 is the residue 21;
- R1 is H and R2 is the residue 22;
- R2 is H and R1 is the residue 22;
- R1 is H and R2 is the residue 23;
- R2 is H and R1 is the residue 23;
- R1 is H and R2 is the residue 24;
- R2 is H and R1 is the residue 24;
- R1 is H and R2 is the residue 25;
- R2 is H and R1 is the residue 25;
- R1 is H and R2 is the residue 26;
- R2 is H and R1 is the residue 26;
- R1 is H and R2 is the residue 27;
- R2 is H and R1 is the residue 27;
- and
- R1 is H and R2 is the residue 28;
- R2 is H and R1 is the residue 28;
39 more elements
Dependencies are inferred from the claim text.